Clinical trials: Refractory Metastatic Colorectal Cancer
Colorectal Cancer
Azacitidine and CAPOX in Metastatic Colorectal Cancer
The goal of the Phase I portion of this study is to find the highest tolerable dose of azacitidine combined with capecitabine and oxaliplatin (CAPOX) that can be given to patients with metastatic colorectal cancer.
- Trial name
- NCT01193517
- Testing
- Azacitidine, Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Unresectable Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer
A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients
COPERNIC is an international, multicentre, single-arm study. Chemo-refractory mCRC subjects who meet all eligibility criteria will be treated with standard systemic chemotherapy (the decision about the treatment regimen being…
- Conditions
- Unresectable Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer, Candidate for Third-line or Subsequent Lines of Therapy
- Trial name
- COPERNIC (NCT05487248)
- Testing
- Blood Sample Collection
- Where
- 12 sites in Belgium, France
- Volunteers
- 103 people
- Sponsor
- Jules Bordet Institute
Colorectal Cancer
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
This will be a randomized phase II clinical trial of patients with histologic documentation of metastatic colorectal cancer, who have received local and currently approved standard therapies, excluding RGF.
- Trial name
- NCT02316340
- Testing
- Vorinostat, Hydroxychloroquine, Regorafenib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Colorectal Cancer
Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003
A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with Penpulimab (AK105) in patients with Chemo-refractory Metastatic Colorectal Cancer (mCRC)
- Trial name
- ALTER-C003 (NCT04970914)
- Testing
- Anlotinib, Penpulimab
- Where
- 8 sites in China
- Volunteers
- 32 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Colorectal Cancer
Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients
This is a Phase Ib study to evaluate the safety and preliminary anti-tumor activity of pembrolizumab in combination with pemetrexed with or without oxaliplatin in patients with chemo-refractory microsatellite stable (MSS)…
- Trial name
- NCT03626922
- Testing
- Pembrolizumab, Pemetrexed, Oxaliplatin
- Where
- 15 sites in United States
- Volunteers
- 33 people
- Sponsor
- NSABP Foundation Inc
Metastatic Colorectal Cancer
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
A post marketing surveillance, prospective study to collect safety information from 250 subjects with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type metastatic colorectal cancer treated with Erbitux as final…
- Trial name
- NCT01134640
- Where
- 15 sites in Taiwan
- Volunteers
- 286 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Cancer
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
This clinical trial aims to evaluate the efficacy, safety of Pyrotinib in combination with trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
- Trial name
- NCT03843749
- Testing
- Pyrotinib
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Changzheng Hospital
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC)
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1…
- Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- Trial name
- NCT02649790
- Testing
- KPT-8602, ASTX727, Dexamethasone
- Where
- 46 sites in United States, Canada and 3 more
- Volunteers
- 277 people
- Sponsor
- Karyopharm Therapeutics Inc
Metastatic Colorectal Adenocarcinoma
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Managements for refractory proficient mismatch repair (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) were still challenging and controversial.
- Trial name
- NCT05942768
- Testing
- regorafenib plus anti-PD-1 antibodies
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Hunan Cancer Hospital
Liver Metastasis, Colorectal Neoplasms
Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases
The purpose of this study is to determine whether the Litx platform is safe and effective in the treatment of liver metastasis arising from colorectal cancer.
- Conditions
- Liver Metastasis, Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastasis
- Trial name
- NCT00068068
- Testing
- Talaporfin sodium (LS11), LED-based light infusion device, Light emitting diodes (LED)
- Where
- 6 sites in United States, Germany
- Volunteers
- 25 people
- Sponsor
- Light Sciences LLC
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
This is a Phase II, open label, single-arm trial study of adding hydroxychloroquine to encorafenib and cetuximab in patients with metastatic BRAF V600E colon cancer with progression on at least 1 prior line of therapy.
- Conditions
- Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
- Trial name
- NCT05576896
- Testing
- Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Northwestern University
Refractory Metastatic Colorectal Cancer
Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial
This study is an investigator-initiated, prospective, multicenter, randomized, controlled, open-label, non-inferiority trial designed to evaluate the efficacy and safety of trifluridine/tipiracil plus fruquintinib versus…
- Trial name
- NCT07261709
- Testing
- Trifluridine/tipiracil plus fruquintinib, trifluridine/tipiracil plus bevacizumab
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies
To determine the rate of response and duration of reponse following therapy with Aroplatin in subjects with advanced colorectal cancer resistant to standard therapies.
- Trial name
- NCT00043199
- Testing
- Aroplatin (Liposomal NDDP, L-NDDP)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aronex Pharmaceuticals
Refractory Metastatic Colorectal Cancer, pMMR
QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer
This is a single-arm,open-label, prospective, single-center Study of QL1101 and JS001 in patients with pMMR/MSS refractory metastatic colorectal cancer.
- Conditions
- Refractory Metastatic Colorectal Cancer, pMMR, MSS
- Trial name
- BEVTOR (NCT04527068)
- Testing
- Bevacizumab, Tripleitriumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Solid Tumors
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
This phase I dose escalation study is intended to define the safety, tolerability and maximal tolerable dose (MTD) of MT110 in patients with advanced solid tumors.
- Trial name
- MT110-101 (NCT00635596)
- Testing
- MT110
- Where
- 4 sites in Germany
- Volunteers
- 65 people
- Sponsor
- Amgen Research (Munich) GmbH
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
MSS Metastatic Colorectal Cancers, MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy
This study is a single-center prospective exploratory research, aiming to identify clinical characteristics and biomarkers associated with the therapeutic effects of dual PD1/PDL1 and CTLA4 blockade plus anti-angiogenic therapy…
- Trial name
- NCT06549907
- Testing
- Multi-omics testing, MRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Cancer Hospital & Institute
Refractory Metastatic Colorectal Cancer, pMMR
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair…
- Conditions
- Refractory Metastatic Colorectal Cancer, pMMR, MSS
- Trial name
- NCT05733611
- Testing
- RP2, RP3, atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Replimune, Inc.
Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
This phase II trial studies circulating cell-free tumor DNA testing to guide treatment with regorafenib or TAS-102 in patients with colorectal cancer that has spread to other areas of the body.
- Conditions
- Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8
- Trial name
- NCT03844620
- Testing
- Best Practice, Laboratory Procedure, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center